Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial

Launched by ANRS, EMERGING INFECTIOUS DISEASES · Jul 25, 2024

Keywords

ClinConnect Summary

The HPVsign study is looking to understand how certain types of the human papillomavirus (HPV), which can lead to serious health issues like high-grade lesions and anal cancer, affect people over time. Specifically, this study will evaluate participants from a previous clinical trial called ANRS IPERGAY to see how many have developed these conditions ten years after joining. The researchers will use a special examination called high-resolution anoscopy to assess any changes or developments in participants' health.

To be eligible for this study, individuals need to have previously participated in the HPV sub-study of the ANRS IPERGAY trial, be between 65 and 74 years old, and provide written consent to participate. Those who are under legal guardianship or receiving state medical assistance are not eligible. If you join the study, you can expect to undergo health assessments related to HPV and its potential effects on your health since your last involvement in the ANRS IPERGAY trial. This research is important as it can help improve the understanding of HPV-related health risks and guide future care for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study;
• • Informed and written signed consent
• • Participant with regular health insurance
• Exclusion Criteria:
• • Participant under guardianship or curatorship
• • Participant with free State medical assistance
• • Participant who disagrees with the use of data collected as part of their participation in the ANRS IPERGAY trial.